Suppr超能文献

脓毒症病理生理学中的纤溶酶原系统:即将到来的生物标志物。

Plasminogen System in the Pathophysiology of Sepsis: Upcoming Biomarkers.

机构信息

Department of Translational Medical Sciences, University of Naples "Federico II", 80138 Naples, Italy.

Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.

出版信息

Int J Mol Sci. 2023 Aug 3;24(15):12376. doi: 10.3390/ijms241512376.

Abstract

Severe hemostatic disturbances and impaired fibrinolysis occur in sepsis. In the most serious cases, the dysregulation of fibrinolysis contributes to septic shock, disseminated intravascular coagulation (DIC), and death. Therefore, an analysis of circulating concentrations of pro- and anti-fibrinolytic mediators could be a winning strategy in both the diagnosis and the treatment of sepsis. However, the optimal cutoff value, the timing of the measurements, and their combination with coagulation indicators should be further investigated. The purpose of this review is to summarize all relevant publications regarding the role of the main components of the plasminogen activation system (PAS) in the pathophysiology of sepsis. In addition, the clinical value of PAS-associated biomarkers in the diagnosis and the outcomes of patients with septic syndrome will be explored. In particular, experimental and clinical trials performed in emergency departments highlight the validity of soluble urokinase plasminogen activator receptor (suPAR) as a predictive and prognostic biomarker in patients with sepsis. The measurements of PAI-I may also be useful, as its increase is an early manifestation of sepsis and may precede the development of thrombocytopenia. The upcoming years will undoubtedly see progress in the use of PAS-associated laboratory parameters.

摘要

严重的止血紊乱和纤溶功能受损发生在脓毒症中。在最严重的情况下,纤溶失调会导致脓毒性休克、弥散性血管内凝血 (DIC) 和死亡。因此,分析循环中促凝和抗纤溶介质的浓度可能是脓毒症诊断和治疗的制胜策略。然而,还需要进一步研究最佳截断值、测量时间及其与凝血指标的组合。本综述的目的是总结有关纤溶酶原激活系统 (PAS) 主要成分在脓毒症病理生理学中的作用的所有相关出版物。此外,还将探讨 PAS 相关生物标志物在脓毒症综合征患者的诊断和结局中的临床价值。特别是在急诊科进行的实验和临床试验强调了可溶性尿激酶型纤溶酶原激活物受体 (suPAR) 作为脓毒症患者预测和预后生物标志物的有效性。PAI-I 的测量也可能有用,因为其增加是脓毒症的早期表现,可能早于血小板减少的发生。未来几年,PAS 相关实验室参数的应用无疑将取得进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2356/10418678/98131587199f/ijms-24-12376-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验